

***Fiscal Year 2024 Department of Defense Rare Cancers Research Program  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Concept Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><a href="#">HT942524RCRPCA</a></p>	<p>Investigators at or above the level of postdoctoral fellow</p>	<ul style="list-style-type: none"> <li>• Supports high-risk/high-reward research that is in the earliest stages of idea development or an untested theory that addresses an important problem related to rare cancers. Proof-of-concept is the anticipated outcome.</li> <li>• Reviewers will be blinded to the identity of the Principal Investigator, collaborators and their organization(s).</li> <li>• Submission must address at least one of the FY24 focus areas of Biology and Etiology, Research Model, and/or Therapy.</li> <li>• <b>Preliminary data are not required.</b></li> <li>• Clinical trials are not allowed.</li> <li>• <b><i>Submission of a letter of intent is required prior to full application submission.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$100,000</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>2</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> July 15, 2024 5:00 p.m. Eastern time</p> <p><b>Application:</b> August 26, 2024 11:59 p.m. Eastern time</p>
<p><b>Idea Development Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><a href="#">HT942524RCRPIDA</a></p>	<p>Investigators at or above the level of Assistant Professor</p>	<ul style="list-style-type: none"> <li>• Supports high-risk/high-reward research with the potential to yield impactful data in the rare cancers field.</li> <li>• Submission must address at least one of the FY24 focus areas of Biology and Etiology, Research Model, and/or Therapy.</li> <li>• <b>Preliminary data with disease-specific rationale (may include correlatives studies to ongoing clinical research) to support the feasibility of the research hypotheses and research approaches are required; however, these data may be derived from studies of the proposed rare cancer type(s)/subtype(s) under study.</b></li> <li>• Clinical trials are not allowed.</li> <li>• <b><i>Pre-application submission is required; application submission is by invitation only.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$350,000</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>3</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> June 17, 2024 5:00 p.m. Eastern time</p> <p><b>Application:</b> September 23, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Resource and Community Development Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li><a href="#">Program Announcement</a></li> <li><a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><a href="#">HT942524RCRPRCDA</a></p>	<p>Investigators at or above the level of Assistant Professor</p>	<ul style="list-style-type: none"> <li>Supports platform development or infrastructure that can be applied to type(s) or sub-type(s) of rare cancers.</li> <li>Research must emphasize research resources development to facilitate collaboration and information sharing among stakeholders such as researchers, patients, family members, caregivers, clinicians and other members of the rare cancers community.</li> <li>Preliminary data are not required but may be included (translational research and clinical studies may be included).</li> <li>Submission must address the FY24 focus area of Platform Development.</li> <li><b>Clinical trials are not allowed.</b></li> <li><b><i>Pre-application submission is required; application submission is by invitation only.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$800,000</b> for direct costs.</li> <li>Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> <li>The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> June 17, 2024 5:00 p.m. Eastern time</p> <p><b>Application:</b> September 23, 2024 11:59 p.m. Eastern time</p>